Epigenetic targeting in oral squamous cell carcinoma: mechanisms, therapies, and translational potential.

IF 2.8 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2025-10-07 DOI:10.1080/14737140.2025.2570164

Junting Yang, Xiaoru Yan, Xiaotang Wang, Xiaoqi Chang, Jiping Gao, Guohua Song

{"title":"Epigenetic targeting in oral squamous cell carcinoma: mechanisms, therapies, and translational potential.","authors":"Junting Yang, Xiaoru Yan, Xiaotang Wang, Xiaoqi Chang, Jiping Gao, Guohua Song","doi":"10.1080/14737140.2025.2570164","DOIUrl":null,"url":null,"abstract":"Introduction: Oral squamous cell carcinoma (OSCC) is a heterogeneous malignancy with rapid progression, limited therapeutic options, and poor prognosis. Epigenetic alterations - including DNA methylation, histone modifications, and noncoding RNA (ncRNA) regulation - are key drivers of oncogene activation and tumor suppressor silencing, offering novel therapeutic opportunities.Areas covered: This review summarizes the major epigenetic mechanisms in OSCC and highlights recent progress in therapeutic agents and molecular targets. In particular, we emphasize ncRNA-based modulators, such as microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), which play crucial roles in epigenetic regulation and represent promising therapeutic candidates. Innovative delivery strategies, including exosome-mediated transfer and nanoparticle formulations, are discussed for their potential to improve treatment specificity and overcome resistance. An updated summary of clinical trials targeting epigenetic regulators in OSCC is also presented, along with possible combination strategies to enhance clinical outcomes.Expert commentary: Epigenetic therapies hold significant promise for precision treatment of OSCC. Combining targeted agents with advanced delivery systems may accelerate clinical translation, while validated biomarkers could support early detection, risk stratification, and personalized therapy.A literature search was conducted in PubMed and ClinicalTrials.gov from January 2002 to July 2025 to identify high-quality studies on epigenetic therapies in OSCC.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-18"},"PeriodicalIF":2.8000,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2570164","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Oral squamous cell carcinoma (OSCC) is a heterogeneous malignancy with rapid progression, limited therapeutic options, and poor prognosis. Epigenetic alterations - including DNA methylation, histone modifications, and noncoding RNA (ncRNA) regulation - are key drivers of oncogene activation and tumor suppressor silencing, offering novel therapeutic opportunities.

Areas covered: This review summarizes the major epigenetic mechanisms in OSCC and highlights recent progress in therapeutic agents and molecular targets. In particular, we emphasize ncRNA-based modulators, such as microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), which play crucial roles in epigenetic regulation and represent promising therapeutic candidates. Innovative delivery strategies, including exosome-mediated transfer and nanoparticle formulations, are discussed for their potential to improve treatment specificity and overcome resistance. An updated summary of clinical trials targeting epigenetic regulators in OSCC is also presented, along with possible combination strategies to enhance clinical outcomes.

Expert commentary: Epigenetic therapies hold significant promise for precision treatment of OSCC. Combining targeted agents with advanced delivery systems may accelerate clinical translation, while validated biomarkers could support early detection, risk stratification, and personalized therapy.A literature search was conducted in PubMed and ClinicalTrials.gov from January 2002 to July 2025 to identify high-quality studies on epigenetic therapies in OSCC.

查看原文本刊更多论文

口腔鳞状细胞癌的表观遗传靶向：机制、治疗和转化潜力。

口腔鳞状细胞癌（OSCC）是一种异质性恶性肿瘤，进展迅速，治疗选择有限，预后差。表观遗传改变-包括DNA甲基化，组蛋白修饰和非编码RNA （ncRNA）调控-是癌基因激活和肿瘤抑制基因沉默的关键驱动因素，提供了新的治疗机会。涵盖领域：本文综述了OSCC的主要表观遗传机制，并重点介绍了治疗药物和分子靶点的最新进展。我们特别强调基于ncrna的调节剂，如microRNAs （miRNAs）和长链非编码rna (lncRNAs)，它们在表观遗传调控中起着至关重要的作用，并代表着有希望的治疗候选者。创新的递送策略，包括外泌体介导的转移和纳米颗粒配方，讨论了它们提高治疗特异性和克服耐药性的潜力。本文还介绍了针对OSCC中表观遗传调控因子的临床试验的最新总结，以及提高临床结果的可能联合策略。专家评论：表观遗传疗法对OSCC的精确治疗具有重要的前景。将靶向药物与先进的递送系统相结合可以加速临床转化，而经过验证的生物标志物可以支持早期检测、风险分层和个性化治疗。从2002年1月到2025年7月，我们在PubMed和ClinicalTrials.gov上进行了文献检索，以确定关于表观遗传治疗OSCC的高质量研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.